In addition to clinical work in pulmonary and critical care medicine, Michael’s research focuses on clinical and trans- lational asthma, with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmaco- genomics and management of eosinophilic granulomatosis with polyangiitis (EGPA). He has led studies focusing on novel biological agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab. Michael was a member of the Steering Committee and site Principal Investigator for the National Institutes of Health (NIH)-sponsored Asthma Clinical Research Network (ACRN now called AsthmaNet), a multicentre asthma clinical trials consortium. He currently serves as the Principle Investigator of the Denver site of the Precision Intervention in Severe/ Exacerbating Asthma (PRECISE) network. A member of the American Society of Clinical Investigation, Michael has participated in many different task forces related to the study of eosinophilic lung diseases, sponsored by the NIH, the Food and Drug Administration (FDA), the European Respiratory Society (ERS) and the International Eosinophil Society (IES). Michael is currently an Associate Editor of Chest. He has also served as Associate Editor of Allergy as well as on the editorial board of the European Journal of Clinical Investigation. Michael has published more than 250 peer-reviewed manuscripts relating to asthma, EGPA and eosinophilic lung diseases. https://doi.org/10.1183/2312508X.10017721 vii